2 January 2014
Smiths Medical has gained a key US Food and Drug Administration (FDA) approval for a customisable infusion system that helps maintain effective epidural analgesia during labour and delivery or with post-operative pain management.
The FDA 510(k) clearance allows Smiths Medical to market its CADD®-Solis pain management system version 3.0 with Programmed Intermittent Bolus (PIB) and Patient Controlled Analgesics (PCA) delivery in the United States.
PIB medication delivery, using the CADD®-Solis v3.0, consistently administers programmed intermittent boluses (doses) that can be supplemented by the patient, improving pain relief and reducing the need for clinical interventions.
The CADD®-Solis ambulatory infusion system, designed for nurses, anesthesiologists, pharmacists and other hospital personnel, is a state-of-the-art system that meets industry recognised standards for advanced error-reduction features in PCA pumps.
General media enquiries
Contact our global media and communications team at:
Please note – the press team can only answer enquiries from accredited members of the press.
Related articles
Smiths appoints new independent Non-executive Director
Read our latest company news as the Board of Smiths is pleased to announce the appointment of Laurence Mulliez as an independent Non-executive Director, with effect from 1 September 2026.
Find out more
Smiths Group plc – Q3 trading update
Find out more
Smiths Foundation awards £1.3m of charitable grants in 2026
Read our latest company news as the Smiths Foundation awards £1.3m of charitable grants in 2026
Find out more